ArticleCell reports. Medicine2024

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.

Yu Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.